Charline Vauchy
YOU?
Author Swipe
View article: Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trial
Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trial Open
View article: Areal bone mineral density, trabecular bone score and 3D-DXA analysis of proximal femur in psoriatic disease
Areal bone mineral density, trabecular bone score and 3D-DXA analysis of proximal femur in psoriatic disease Open
Objectives To evaluate bone mineral density (BMD) and bone quality, with assessment of the cortical and trabecular compartments, in patients with psoriasis (PsO) alone or with psoriatic arthritis (PsA). Methods Patients with PsA and patien…
View article: Kidney Transplantation After Allogeneic Hematopoietic Cell Transplantation
Kidney Transplantation After Allogeneic Hematopoietic Cell Transplantation Open
View article: Early, Very High-Titre Convalescent Plasma Therapy in Clinically Vulnerable Individuals with Mild COVID-19: An International, Randomised, Open-Label Trial
Early, Very High-Titre Convalescent Plasma Therapy in Clinically Vulnerable Individuals with Mild COVID-19: An International, Randomised, Open-Label Trial Open
View article: Determinants of urgent start dialysis in a chronic kidney disease cohort followed by nephrologists
Determinants of urgent start dialysis in a chronic kidney disease cohort followed by nephrologists Open
Background The French Renal Epidemiology and Information Network (REIN) registry collect dialysis initiation context for each patient starting dialysis with a flawed definition of urgent start dialysis (USD). The main objective of this stu…
View article: POS0440 INCREASED FREQUENCY OF ACTIVATED MAIT CELLS EXPRESSING THE GUT HOMING RECEPTOR CCR9 IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
POS0440 INCREASED FREQUENCY OF ACTIVATED MAIT CELLS EXPRESSING THE GUT HOMING RECEPTOR CCR9 IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS Open
View article: Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19 (COVIC-19): protocol for a randomised, open-label trial
Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19 (COVIC-19): protocol for a randomised, open-label trial Open
Introduction COVID-19 convalescent plasma (CCP) is a possible treatment option for COVID-19. A comprehensive number of clinical trials on CCP efficacy have already been conducted. However, many aspects of CCP treatment still require invest…
View article: Data from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor
Data from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor Open
Purpose: To evaluate CD4+ helper functions and antitumor effect of promiscuous universal cancer peptides (UCP) derived from telomerase reverse transcriptase (TERT).Experimental Design: To evaluate the widespread im…
View article: Supplementary Figure 4 from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor
Supplementary Figure 4 from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor Open
PDF file - 57K, UCPs mediated helper effect on CTLs in other models of vaccinations
View article: Supplementary Figure 1 from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor
Supplementary Figure 1 from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor Open
PDF file - 51K, Isolation of UCP4-specific CD4 Th1 cell clone from a cancer patient
View article: Supplementary Figure 3 from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor
Supplementary Figure 3 from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor Open
PDF file - 38K, Comparison of T-cell help mediated by UCP2 and a HTLV-1 Tax-derived peptide on self/TERT pY988 specific CTL response
View article: Supplementary Methods and Figure Legend from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor
Supplementary Methods and Figure Legend from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor Open
PDF file - 106K
View article: Supplementary Figure 5 from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor
Supplementary Figure 5 from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor Open
PDF file - 26K, UCP2 specific CD4 T cells recognize the mTERT-derived counterpart peptide p568
View article: Supplementary Figure 2 from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor
Supplementary Figure 2 from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor Open
PDF file - 65K, UCP2 and UCP4 peptides increase self/TERT pY572 specific CTL responses
View article: Data from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor
Data from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor Open
Purpose: To evaluate CD4+ helper functions and antitumor effect of promiscuous universal cancer peptides (UCP) derived from telomerase reverse transcriptase (TERT).Experimental Design: To evaluate the widespread im…
View article: Supplementary Figure 3 from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor
Supplementary Figure 3 from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor Open
PDF file - 38K, Comparison of T-cell help mediated by UCP2 and a HTLV-1 Tax-derived peptide on self/TERT pY988 specific CTL response
View article: Supplementary Figure 2 from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor
Supplementary Figure 2 from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor Open
PDF file - 65K, UCP2 and UCP4 peptides increase self/TERT pY572 specific CTL responses
View article: Supplementary Methods and Figure Legend from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor
Supplementary Methods and Figure Legend from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor Open
PDF file - 106K
View article: Supplementary Figure 1 from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor
Supplementary Figure 1 from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor Open
PDF file - 51K, Isolation of UCP4-specific CD4 Th1 cell clone from a cancer patient
View article: Supplementary Figure 4 from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor
Supplementary Figure 4 from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor Open
PDF file - 57K, UCPs mediated helper effect on CTLs in other models of vaccinations
View article: Supplementary Figure 5 from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor
Supplementary Figure 5 from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor Open
PDF file - 26K, UCP2 specific CD4 T cells recognize the mTERT-derived counterpart peptide p568
View article: Mini-Review: The Administration of Apoptotic Cells for Treating Rheumatoid Arthritis: Current Knowledge and Clinical Perspectives
Mini-Review: The Administration of Apoptotic Cells for Treating Rheumatoid Arthritis: Current Knowledge and Clinical Perspectives Open
Rheumatoid arthritis (RA) is a chronic immune-mediated disease managed by conventional synthetic drugs, such as methotrexate (MTX), and targeted drugs including biological agents. Cell-based therapeutic approaches are currently developed i…
View article: AB0121 ASSESSMENT OF GLOBAL DNA METHYLATION IN PERIPHERAL BLOOD CELL SUBPOPULATIONS OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: PRELIMINARY RESULTS
AB0121 ASSESSMENT OF GLOBAL DNA METHYLATION IN PERIPHERAL BLOOD CELL SUBPOPULATIONS OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: PRELIMINARY RESULTS Open
View article: Immune phenotype predicts new onset diabetes after kidney transplantation
Immune phenotype predicts new onset diabetes after kidney transplantation Open
View article: CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin
CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin Open
Immune checkpoint blockade has proven its efficacy in hypermutated subtypes of metastatic colorectal cancers (mCRC). Immunogenic potential can also be observed with conventional chemotherapies, but this property has never been explored tho…
View article: Could Sodium Chloride be an Environmental Trigger for Immune-Mediated Diseases? An Overview of the Experimental and Clinical Evidence
Could Sodium Chloride be an Environmental Trigger for Immune-Mediated Diseases? An Overview of the Experimental and Clinical Evidence Open
Immune mediated diseases (IMDs) are complex chronic inflammatory diseases involving genetic and environmental factors. Salt intake has been proposed as a diet factor that can influence the immune response. Indeed, experimental data report …